NCT04658069|Unknown
T Cell Dysfunction in ESRD
T Cell Dysfunction in End-stage Renal Disease
Loading search results
T Cell Dysfunction in End-stage Renal Disease
Sponsor study identifier
observational
400
0 countries
N/A
Study Start
January 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Patients with end-stage renal disease (ESRD) suffer from high morbidity and mortality of cardiovascular and infectious disease and increased risk of all-cause mortality which is mainly attributed to the disturbed immune response. More and more evident indicated that T cell dysfunction was universal in ESRD. However, few studies clarified the association of T cell dysfunction and clinical outcomes. This study is aim to explore valuable markers of T cell dysfunction predicting bad clinical outcomes including death, cardiovascular disease, infection and tumor. Hopefully, these finding will provide foundation for further mechanism research and better therapeutic options for ESRD patients in the future.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 1, 2020
Actual (reported)December 8, 2020
Actual (reported)January 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Death
mortality during the study
January 2021 to December 2023
Cardiovascular disease
January 2021 to December 2023
Infection event
January 2021 to December 2023
Cancer
January 2021 to December 2023
all HD patients enrolled in this study
no specific interventions
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
* aged 18 years and older * had been on hemodialysis treatment for at least 6 months in our blood purification center
Peripheral blood
Bo Shen, MD
Fudan University
Fangfang Xiang, MD
Fudan University
First Submitted
December 1, 2020
First Posted
December 8, 2020
Study Start
January 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 31, 2023
Estimated (date passed)Dermodialysis as Adjuvant Therapy in Renal Failure
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 31, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 8, 2020
Record last verified: 2020-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: